Daratumumab in multiple myeloma: an overview of 3 key trials

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее

The ELOQUENT-3 Trial in R/R Multiple MyelomaПодробнее

Extrapolating from Clinical Trials: Daratumumab in MMПодробнее

Elotuzumab and Daratumumab in Multiple MyelomaПодробнее

Dr. Landgren on Using Daratumumab for Patients With Multiple MyelomaПодробнее

MAIA and ALCYONE: follow-up of daratumumab in multiple myelomaПодробнее

All About Darzalex (daratumumab)Подробнее

Why daratumumab will become key for the treatment of multiple myelomaПодробнее

Phase 3 study of SC vs IV daratumumab in patients with relapsed or refractory multiple myelomaПодробнее

Results of Phase III POLLUX trial on daratumumab in multiple myelomaПодробнее

Daratumumab in Multiple MyelomaПодробнее

Subcutaneous Daratumumab in R/R Myeloma: The COLUMBA TrialПодробнее

Why daratumumab is effective in multiple myeloma - results from the CASTOR trialПодробнее

The role of daratumumab in the treatment of myeloma and insights into the MAIA trialПодробнее

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple MyelomaПодробнее

Daratumumab in the treatment of multiple myelomaПодробнее

The APOLLO trial: daratumumab for R/R myelomaПодробнее

CASTOR Trial: Daratumumab Combination Doubles Response Rates in Myeloma PatientsПодробнее

Daratumumab, Carfilzomib, Lenalidomide and Dex for HR Smoldering Multiple Myeloma: ASCENT TrialПодробнее

Subcutaneous daratumumab: an update on the latest MM clinical trialsПодробнее